DexCom, Inc. vs iShares Core MSCI EAFE ETF — how do they compare? DexCom, Inc. trades at $89.07 (market cap $33.79B), while iShares Core MSCI EAFE ETF trades at $100.99. Which is the better fit depends on your goals.
| DXCM | IEFA | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $89.53 | $101.09 |
52-Week Low | $54.84 | $84.72 |
Enterprise Value | $33.24B | — |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
IEFA trades at $101.28, up 0.75% today, with a bullish technical outlook from moving averages but overbought RSI signals. The ETF focuses on developed international markets excluding the U.S. and Canada, offering diversification and a dividend yield. Recent news highlights its role in defensive portfolio shifts and comparisons with peers like VXUS and SPGM.
Outlook is positive for diversification seekers amid U.S. concentration risks, supported by lower fees and income appeal. Risks include developed-market economic sensitivity and currency fluctuations. Analyst sentiment is generally favorable for long-term exposure.
Trailing returns across standard periods
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →